International Aspirin Foundation seeks applicants for Senior Science Award 2016

The International Aspirin Foundation, founded in 1974, is seeking applicants for the Senior Science Award 2016.  This is open to scientists who can demonstrate a track record of valuable, significant medical scientific research (basic, translational or clinical), contributing to the scientific knowledge of aspirin/acetylsalicylic acid.

Announcing the opening of the award, Professor Peter Rothwell FMedSci, Chair of The International Aspirin Foundation's Scientific Advisory Board, stated that "this prestigious award recognises scientists who endeavour to better understand what this long-established drug can do to improve human health", he confirmed that "this is an international award and we look forward to receiving applications from around the world".

The applicant needs to produce a statement (maximum 1,000 words), submitted in English, via email to [email protected], summarising their career and contribution to the use and science of aspirin/ acetylsalicylic acid along with a full CV.  Special consideration will be given to research addressing the future use and development of aspirin and unmet medical needs for the benefit of human health.

The deadline for receipt of applications is Tuesday 31st May 2016.  All applications will be reviewed by The International Aspirin Foundation Scientific Advisory Board.

In recognition of the successful applicant's achievements, there will be a presentation ceremony to honour their work.  Applicants should be available on 30th September 2016 to attend an Award Ceremony in London, UK and be prepared to participate in media interests in the event.

The successful applicant will receive an engraved award; £10,000 (ten thousand pounds sterling) and a framed certificate.

Posted in: Healthcare News | Pharmaceutical News




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Specific drug regimen taken prior to surgery reduces risk of cancer recurrence, study finds